ClinicalTrials.gg
RecruitingNCT06405633Updated Nov 16, 2026

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

A Phase 1/2 interventional study of WVE-006 in Alpha-1 Antitrypsin Deficiency, sponsored by Wave Life Sciences USA, Inc.. Recruiting at 9 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Wave Life Sciences USA, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom — 8 open to participants now, 11 under way, 3 of them phase 3. alpha 1-Antitrypsin Deficiency · United Kingdom.

Planned enrollment
15th of 25
48 · median 54
Started
2024
with 4 others
Phase 1/2
4 of 28
3 open now
Primary completion
2027-09
later than 2 of 10 live
Registered
23rd of 28
by date
Lead sponsor
2 of 28
Wave Life Sciences USA, Inc.

Among the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, this one is the 15th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2024, is one of 4 in phase 1/2, reaches primary completion later than 2 of the 10 other live ones, and was the 23rd registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

8 of the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.

03

Conditions studied

  • Alpha-1 Antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as determined by the Investigator, based on a medical evaluation, or has mild to moderate AATD-induced lung disease ( ≥50%) and/or stable mild AATD-induced liver disease (≤F2 (≤10 kPa) on FibroScan.
  • Genetic testing confirming Pi*ZZ.
  • Participant has been a non-smoker for at least 1 year prior to screening.

Exclusion criteria

Exclusion Criteria:

    • Participant has a history of multiple drug allergies or of allergic reaction to an oligonucleotide or to N-acetylgalactosamine (GalNAc).

      • Participant has a history of intolerance or any medical condition that might interfere with subcutaneous injections.
      • Any ongoing or recent infections.
      • Any recent or planned vaccinations during the study.
      • Participant has a history of regular alcohol consumption exceeding 14 standard drinks/week.
      • Unwilling to abstain from alcohol for 48 hours prior to dosing at each of the dosing visits.
      • Any recent or planned major surgery during the study.
      • Participant has any medical condition or social circumstance that, in the opinion of the Investigator, would make the participant unsuitable for participation in the study or for dosing on Day 1, or could interfere with the assessments of safety, pharmacodynamics, or pharmacokinetics, or completion of the study.
      • Participant currently on AAT augmentation therapy, planned to be on augmentation therapy anytime during the study, or has been on augmentation therapy within 30 days prior to Screening Visit.
      • Donation of blood or blood products in excess of 500 mL within 12 weeks prior to Screening Visit and/or unwilling to refrain from blood donation for the duration of the study.
      • Participant has received an agent within 3 months of the Screening Visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    WVE-006 (Dose 1)

    Drug: WVE-006

  • Experimental
    WVE-006 (Dose 2)

    Drug: WVE-006

  • Experimental
    WVE-006 (Dose 3)

    Drug: WVE-006

  • Experimental
    WVE-006 (Dose 4)

    Drug: WVE-006

  • Experimental
    WVE-006 (Dose 5)

    Drug: WVE-006

Interventions

  • DrugWVE-006

    RNA editing oligonucleotide

06

What researchers measure

Primary outcomes

  1. The proportion of participants with adverse events

    Time frame: Up to 36 Weeks

Secondary outcomes

  1. Single Ascending Dose - Change from baseline in levels of serum M-AAT protein.

    Time frame: Up to 12 Weeks

  2. Multiple Ascending Dose - Change from baseline in levels of serum M-AAT protein

    Time frame: Up to 24 Weeks

  3. Single Ascending Dose - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast)

    Time frame: Up to 12 Weeks

  4. Single Ascending Dose - Maximum concentration of WVE-006 in plasma

    Time frame: Up to 12 Weeks

  5. Multiple Ascending Doses - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast)

    Time frame: Up to 24 Weeks

  6. Multiple Ascending Doses - Maximum concentration of WVE-006 in plasma (Cmax)

    Time frame: Up to 24 Weeks

07

Study locations

4 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2024 (actual). Primary completion is estimated for Sep 2027, 38 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2024
First posted
May 8, 2024
StartActual
Jul 19, 2024
Primary completionEst.
Sep 2027was Sep 2026
CompletionEst.
Sep 2027was Sep 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 19, 2026
Sites
9 sites changed recruiting status (5 now active, not recruiting, 4 now recruiting)
Show 9 sites
  • St. Vincent's Hospital, Melbourne · Fitzroy, Australiano status→Recruiting
  • Dalhousie University - Queen Elizabeth II Health Sciences Centre · Halifax, Canadano status→Recruiting
  • Inspiration Research Limited · Toronto, Canadano status→Recruiting
  • Turku University Hospital · Turku, Finlandno status→Active, not recruiting
  • Universitaetsklinikum Aachen, AoeR · Aachen, Germanyno status→Active, not recruiting
  • Waikato Hospital · Hamilton, New Zealandno status→Recruiting
  • Queen Elizabeth Hospital, University Hospital Birmingham · Birmingham, United Kingdomno status→Active, not recruiting
  • Cambridge University - Addenbrooke's Hospital · Cambridge, United Kingdomno status→Active, not recruiting
  • Royal Free London NHS Foundation Trust · London, United Kingdomno status→Active, not recruiting
across 2 updates, Oct 19, 2026 – Nov 16, 2026
Primary completion
Sep 2026→Sep 2027
Oct 19, 2026
Study completion
Sep 2026→Sep 2027
Oct 19, 2026
Enrollment
24→48
Oct 19, 2026
Interventions
Arms added: WVE-006 (Dose 4)·WVE-006 (Dose 5)
Oct 19, 2026
Contact
Study contact now listed: added C•••@wavelifesci.com · •••4687. See the current contact
Oct 19, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Inspiration Research Limited · Toronto, CanadaContact added k•••@inspirationresearch.caContact added d•••@inspirationresearch.ca
  • St. Vincent's Hospital, Melbourne · Fitzroy, AustraliaContact added S•••@svha.org.au
  • Dalhousie University - Queen Elizabeth II Health Sciences Centre · Halifax, CanadaContact added S•••@nshealth.ca
  • Waikato Hospital · Hamilton, New ZealandContact added C•••@waikatodhb.health.nz
across 2 updates, Oct 19, 2026 – Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • St. Vincent's Hospital, Melbourne · Fitzroy, AustraliaActive, not recruiting→Recruiting
    • Dalhousie University - Queen Elizabeth II Health Sciences Centre · Halifax, CanadaActive, not recruiting→Recruiting
    • Waikato Hospital · Hamilton, New ZealandActive, not recruiting→Recruiting
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • St. Vincent's Hospital, Melbourne · Fitzroy, AustraliaContact added S•••@svha.org.au
    • Dalhousie University - Queen Elizabeth II Health Sciences Centre · Halifax, CanadaContact added S•••@nshealth.ca
    • Waikato Hospital · Hamilton, New ZealandContact added C•••@waikatodhb.health.nz
    + 1 other change: verification date
  2. Oct 19, 2026
    Active, not recruiting→Recruiting
    9 sites changed recruiting status (8 now active, not recruiting, 1 now recruiting)
    Show 9 sites
    • St. Vincent's Hospital, Melbourne · Fitzroy, Australiano status→Active, not recruiting
    • Dalhousie University - Queen Elizabeth II Health Sciences Centre · Halifax, Canadano status→Active, not recruiting
    • Inspiration Research Limited · Toronto, Canadano status→Recruiting
    • Turku University Hospital · Turku, Finlandno status→Active, not recruiting
    • Universitaetsklinikum Aachen, AoeR · Aachen, Germanyno status→Active, not recruiting
    • Waikato Hospital · Hamilton, New Zealandno status→Active, not recruiting
    • Queen Elizabeth Hospital, University Hospital Birmingham · Birmingham, United Kingdomno status→Active, not recruiting
    • Cambridge University - Addenbrooke's Hospital · Cambridge, United Kingdomno status→Active, not recruiting
    • Royal Free London NHS Foundation Trust · London, United Kingdomno status→Active, not recruiting
    Primary completion Sep 2026→Sep 2027
    Study completion Sep 2026→Sep 2027
    Enrollment 24→48
    Interventions Arms added: WVE-006 (Dose 4)·WVE-006 (Dose 5)
    Contact Study contact now listed: added C•••@wavelifesci.com · •••4687. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Inspiration Research Limited · Toronto, CanadaContact added k•••@inspirationresearch.caContact added d•••@inspirationresearch.ca
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06405633
Lead sponsor
Wave Life Sciences USA, Inc.
Responsible party
Sponsor
First posted
May 8, 2024
Start date
Jul 19, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Clinical Operations
Contact
Clinicaltrials@wavelifesci.com
855-215-4687
Medical Director, MD
study director · Wave Life Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion